Device Trial Radar · NCT07928674
Prehospital mSOFA-Kit Decision Support for the Detection of Multiple Organ Failure
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
3,780
Planned (sponsor's estimate)
Start
Apr 1, 2027
Primary completion
Oct 31, 2029
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- University of ValladolidAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Instituto de Salud Carlos III; Gerencia Regional de Salud de Castilla y Leon
- First posted
- Nov 10, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Health services research
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn whether the mSOFA-Kit, a decision support system that calculates the modified Sequential Organ Failure Assessment (mSOFA) score on scene, improves the outcomes of adults attended by Advanced Life Support Units (USVA) for a potentially critical condition. The main question it aims to answer is: does systematic on-scene stratification of multiorgan risk with the mSOFA-Kit reduce the 2-day composite adverse outcome (all-cause mortality, in-hospital cardiac arrest, admission to a level 2 or 3 ICU, invasive mechanical ventilation or renal replacement therapy) compared with the standard XABCDE assessment? Researchers will compare USVAs using the mSOFA-Kit with a visible score (intervention arm) with USVAs applying standard XABCDE care with a blinded mSOFA score (control arm). Ambulance units, not individual patients, are randomly assigned to each arm. In both arms, a small venous blood sample, obtained from the peripheral venous catheter already placed for clinical care, is analyzed on scene with a point-of-care analyzer. Participants will: * receive the usual prehospital care of their emergency service; * have their on-scene data and their hospital outcomes recorded; * be followed up to 90 days through medical records and death registries.
Conditions
- Multiple Organ Failure
- Critical Illness
Interventions
mSOFA-KitDevice
Decision support system whose core is the mSOFA-App (Software as a Medical Device, Class IIb). From a venous point-of-care blood test (epoc NXS analyzer) and the vital signs of the USVA monitor, it automatically calculates the mSOFA score (0-17), stratifies the patient into 5 risk levels and displays protocol-based recommendations; it also supports structured pre-alert to the receiving hospital.
Standard XABCDE assessmentOther
Standard prehospital care protocol (eXsanguination, Airway, Breathing, Circulation, Disability, Exposure) of each emergency medical service, with the point-of-care blood test available to the professional but without calculation or display of the mSOFA score.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite adverse outcome at 2 daysTime frame: 48 hours (+/- 6 hours) after hospital admission
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gerencia de Emergencias Sanitarias de Castilla y León
Valladolid, Castille and León, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.